Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stojadinovic, A.
Right arrow Articles by Shaha, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stojadinovic, A.
Right arrow Articles by Shaha, A. R.
Related Collections
Right arrow Other Endocrine
Annals of Surgical Oncology 9:197-203 (2002)
© 2002 Society of Surgical Oncology

ORIGINAL ARTICLES

Hürthle Cell Carcinoma: A 60-Year Experience

Alexander Stojadinovic, MD, Axel Hoos, MD, PhD, Ronald A. Ghossein, MD, Marshall J. Urist, Denis H. Y. Leung, PhD, Ronald H. Spiro, MD, Jatin P. Shah, MD, Murray F. Brennan, MD, Bhuvanesh Singh, MD and Ashok R. Shaha, MD

From the Departments of Surgery (AS, AH, MJU, RHS, JPS, MFB, BS, ARS), Pathology (RAG), and Biostatistics (DHYL), Memorial Sloan-Kettering Cancer Center, New York, New York.

Correspondence: Address correspondence and reprint requests to: Ashok R. Shaha, MD, Professor of Surgery, Head and Neck Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021; Fax: 212-717-3302; E-mail: shahaa{at}mskcc.org

Background: The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC).

Methods: Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Data were analyzed with the Kaplan-Meier method and by log-rank test.

Results: The extent of thyroid resection did not predict outcome. Recurrence was a significant predictor of tumor-related mortality. Significant adverse predictors of RFS and DSS were degree of invasion, size >4 cm, extrathyroidal extension, and initial nodal or distant metastases. The most significant predictor of outcome was extent of invasion. Eight-year RFS values for low- and high-risk groups were 100% and 24%. Corresponding rates of 8-year DSS were 100% and 58%.

Conclusions: Widely invasive HCC is an aggressive malignancy that identifies patients who are at high risk for recurrence and tumor-related death. Patients with HCC have a prognosis that is reliably predicted by degree of invasion, tumor size, extrathyroidal disease extension, and initial nodal or distant metastasis. Recurrence portends a poor outcome. High-risk patients and those with recurrence should be considered for adjuvant therapy.

Key Words: Hürthle cell • Thyroid cancer • Disease recurrence • Survival




This article has been cited by other articles:


Home page
 JNMHome page
D. A. Pryma, H. Schoder, M. Gonen, R. J. Robbins, S. M. Larson, and H. W.D. Yeung
Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients
J. Nucl. Med., August 1, 2006; 47(8): 1260 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
E. L. Maxwell, C. E. Palme, and J. Freeman
Hurthle Cell Tumors: Applying Molecular Markers to Define a New Management Algorithm
Arch Otolaryngol Head Neck Surg, January 1, 2006; 132(1): 54 - 58.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society of Surgical Oncology.